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Primary testicular lymphoma is a rare lymphoid malignancy, mostoften,  histologically,  representing diffuse large B-cell lymphoma.The tumor microenvironment and limited immune surveillance
have a major impact on diffuse large B-cell lymphoma pathogenesis and
survival, but the impact on primary testicular lymphoma is unknown.
Here, the purpose of the study was to characterize the tumor microen-
vironment in primary testicular lymphoma, and associate the findings
with outcome. We profiled the expression of 730 immune response
genes in 60 primary testicular lymphomas utilizing the Nanostring plat-
form, and used multiplex immunohistochemistry to characterize the
immune cell phenotypes in the tumor tissue. We identified a gene signa-
ture enriched for T-lymphocyte markers differentially expressed
between the patients. Low expression of the signature predicted poor
outcome independently of the International Prognostic Index (progres-
sion-free survival: HR=2.810, 95%CI: 1.228-6.431, P=0.014; overall sur-
vival: HR=3.267, 95%CI: 1.406-7.590, P=0.006). The T-lymphocyte sig-
nature was associated with outcome also in an independent diffuse large
B-cell lymphoma cohort (n=96). Multiplex immunohistochemistry
revealed that poor survival of primary testicular lymphoma patients cor-
related with low percentage of CD3+CD4+ and CD3+CD8+ tumor-infil-
trating lymphocytes (P<0.001). Importantly, patients with a high T-cell
inflamed tumor microenvironment had a better response to rituximab-
based immunochemotherapy, as compared to other patients.
Furthermore, loss of membrane-associated human-leukocyte antigen
complexes was frequent and correlated with low T-cell infiltration. Our
results demonstrate that a T-cell inflamed tumor microenvironment
associates with favorable survival in  primary testicular lymphoma. This
further highlights the importance of immune escape as a mechanism of
treatment failure.
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ABSTRACT
Introduction
Primary testicular lymphoma (PTL) is a rare and aggressive lymphoid malignan-
cy; the majority of the cases are diffuse large B-cell lymphomas (DLBCL).1 Patients
with PTL have a substantial risk of recurrence and a tendency of lymphoma
involvement in additional extranodal sites, such as contralateral testis and the cen-
tral nervous system (CNS). Most cases are classified as non-germinal center (non-
GC) cell-of-origin subtype, which may partially account for the aggressive nature
of the disease. The current standard of care consists of rituximab, cyclophos-
phamide, doxorubicin, vincristine, and prednisone (R-
CHOP) immunochemotherapy, CNS prophylaxis, and
locoregional radiotherapy or surgery of the remaining con-
tralateral testicle. While the addition of rituximab to  sys-
temic chemotherapy has improved the overall prognosis
of DLBCL, treatment responses in PTL have not been
equally evident.1,2
The tumor microenvironment (TME) and limited
immune surveillance play important roles in the lym-
phoma pathogenesis and survival.3,4 The TME of B-cell
lymphomas consists of immune cells [e.g. T cells,
macrophages, natural killer (NK) cells], stromal cells, blood
vessels, and extracellular matrix. The TME may confer
effective tumor recognition and clearance, but on the
other hand, can also provide a protective niche for the
tumor cells, and facilitate cell proliferation and survival.5
The interactions between lymphoma cells and the TME
contribute to the ability of tumor cells to escape host
immune surveillance; these mechanisms include loss of
expression of human leukocyte antigen (HLA) class I and
II molecules that interferes with correct tumor cell recog-
nition by the cellular immune system and may provide
tumor cells with an escape mechanism.6 Several studies
have reported loss of HLA I and II expression in B-cell
lymphomas, including PTL.7-11 Another immune escape
mechanism is the expression of immune checkpoint mol-
ecules, such as programmed cell death 1 (PD-1) and the
cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4).6
In this study, we aimed to characterize cellular and
molecular immunological profiles in PTL, and associate
the findings with outcome. We identified a gene signature
enriched for T-cell- and NK-cell-related genes, the low
expression of which predicts high risk of recurrence and
mortality in patients with PTL and DLBCL. Our results
emphasize the key role of the TME and immune escape in
regulating therapy resistance in aggressive B-cell lym-
phomas.
Methods
Patients' characteristics and samples
The study consisted of formalin-fixed paraffin-embedded
(FFPE) samples from primary orchiectomy of 60 patients diag-
nosed with PTL in 1993-2013 (Table 1). Twenty-eight of the
patients were diagnosed and treated in the pre-rituximab era with
anthracyclin-based chemotherapy, whereas 32 of the patients
were treated with rituximab-containing immunochemotherapy.
In addition, 34 patients received CNS prophylaxis, consisting
mainly of intravenously administered high-dose methotrexate
and/or high-dose cytarabine. Nineteen patients received treatment
of the contralateral testicle (radiotherapy or orchiectomy). The
cell-of-origin (COO) was determined by immunohistochemistry
using the Hans algorithm.12 The study was approved by the Ethics
Committees in Helsinki and Tampere, Finland, and by the Finnish
National Authority for Medicolegal Affairs, and by the
Institutional Review Boards of the institutes involved in the study. 
The dataset of primary DLBCL from the Cancer Genome
Characterization Initiative (CGCI) (the database of Genotypes
and Phenotypes study accession: phs000532.v2.p1; n=96)13 was
used for comparison (Table 1).
Gene expression analysis 
Gene expression from the FFPE samples of 60 PTL patients was
profiled with the Nanostring nCounter Human PanCancer
Immunoprofiling Panel (XT-CSO-HIP1-12, NanoString
Technologies, Seattle, WA, USA). The detailed protocol is provid-
ed in the Online Supplementary Methods.
Immunohistochemistry
Formalin-fixed paraffin-embedded  tissue microarray (TMA)
was utilized for the immunohistochemical (IHC) analyses. The
protocol for HLA-ABC, HLA-DR, and β2 microglobulin staining
is provided in the Online Supplementary Methods. Membranous
staining in the majority (>90%) of tumor cells was scored as nor-
mal (highly positive). Cases with mixed cytoplasmic and mem-
branous staining were scored as moderately positive. Cases with
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Table 1. Patients’ characteristics of the primary testicular lymphoma
(PTL) and diffuse large B-cell lymphomas (DLBCL).
Characteristics PTL cohort DLBCL cohort
All n (%) All n (%)
Number of patients 60 (100) 96 (100)
Age
<60 years 16 (27) 41 (43)
≥60 years 44 (73) 55 (57)
Sex
Men 60 (100) 63 (66)
Women 33 (34)
Molecular subgroup
GCBa 15 (25) 55 (57)
non-GCB 40 (67) 41 (43)
nd 5 (8)
Stage
I-IIb 39 (65) 18 (19)
III-IV 21 (35) 78 (81)
IPI score
0-2 42 (70) 25 (26)
3-5 18 (30) 71 (74)
Elevated LDH 22 (37) n/a
CNS prophylaxis 34 (57) n/a
IV-prophylaxis 31 (52) n/a
IT-prophylaxis 8 (13) n/a
Treated with rituximab-containing regimen 32 (53) 91 (96)
Primary CNS involvement 2 (3) n/a
Relapses 18 (30) 27 (28)
Primary refractoryc 11 (18) n/a
CNS relapse/progression 2 (3) n/a
Systemic and CNS relapse 2 (3) n/a
Systemic relapse/progression 7 (12) n/a
Late relapse 7 (12) n/a
CNS relapse 2 (3) n/a
Systemic and CNS relapse 0 (0) n/a
Systemic relapse 5 (8) n/a
Deaths 25 (42) 24 (25)
Lymphoma-specific 16 (27) 21 (22)
Other 9 (15) 3 (3)
aGCB; germinal-center B cell; nd: not determined; LDH: lactate dehydrogenase; n/a:
not assigned; CNS: central nervous system; IV: intravenous; IT: intrathecal. bIsolated
bilateral testicular involvement was defined as stage IAE. cRelapse/progression less
than 12 months after the diagnosis and/or within 6 months from the end of primary
treatment.
no membranous staining were scored as negative. When deter-
mining the triple-positive cases, the highly and moderately pos-
itive groups were merged. Scoring was performed independent-
ly by  MA and SMa.
Multiplex immunohistochemistry (mIHC) using a panel with
antibodies for CD3 (clone EP449E, Abcam), CD4 (clone
EPR6855, Abcam), CD8 (clone C8/144B, Abcam), CD56 (clone
MRQ-42, Cell Marque, Rocklin, CA, USA) was performed as
previously described.14 Further details are provided in the Online
Supplementary Methods. The digital image analysis platform
CellProfiler 2.1.215 was used for cell segmentation, intensity
measurements, and immune cell classification. Marker co-local-
ization was computed with the single-cell analysis software
FlowJo v.10 (FlowJo LLC.). Spots with less than 5000 cells were
excluded from analysis and duplicate spots from the same
patient merged.
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Table 2. Pathways enriched among T-lymphocyte signature genes.
Term P
h_thelperPathway:T Helper Cell Surface Molecules 9.74E-04
h_tcytotoxicPathway:T Cytotoxic Cell Surface Molecules 9.74E-04
h_no2il12Pathway:NO2-dependent IL 12 Pathway in NK cells 0.001542
h_ctlPathway:CTL mediated immune response against target cells 0.003803
h_tcraPathway:Lck and Fyn tyrosine kinases in initiation of TCR Activation 0.013718
h_cskPathway:Activation of Csk by cAMP-dependent Protein Kinase Inhibits Signaling through the T Cell Receptor 0.013718
hsa05150:Staphylococcus aureus infection 0.022019
h_tcapoptosisPathway:HIV Induced T Cell Apoptosis 0.028495
hsa04514:Cell adhesion molecules (CAMs) 0.048673
Figure 1. Hierarchical clustering reveals gene signatures dif-
ferentially expressed in primary testicular lymphoma (PTL)
patients. The expression of PanCancer Immune profiling
panel genes was assayed by Nanostring nCounter from 60
PTL samples. The data were z-score transformed and visual-
ized by unsupervised hierarchical clustering using Euclidean
distance. Relative levels of gene expression are depicted
according to the color scale shown. Each row represents a dif-
ferent gene and each column a different sample. Three main
gene signatures were discovered: T-lymphocyte signature,
and Cytokine I and II signatures.
Statistical analysis
Statistical analyses were performed with IBM SPSS v.24.0 (IBM,
Armonk, NY, USA). The χ2 test was used to assess differences in
categorical variables. Mann-Whitney U and Kruskal-Wallis tests
were used to compare differences between two or more groups,
respectively. The Kaplan-Meier method was used to estimate sur-
vival rates (log-rank test). Cox univariate regression analysis was
performed to study the prognostic value of the factors.
Multivariate analyses were performed according to the Cox pro-
portional hazards regression model using categorical data. Overall
survival (OS) and disease-specific survival (DSS) were determined
as the interval from diagnosis to death from any cause or death
due to lymphoma, respectively. Progression-free survival (PFS)
was defined as the period between diagnosis and progression or
death from any cause. Correlation analyses were performed with
Spearman rank analysis. All comparisons were two-tailed, and
P<0.05 was considered significant.
Results
Unsupervised hierarchical clustering reveals genes 
differentially expressed between primary testicular
lymphoma patients
We profiled the expression of 730 immune-associated
genes and 40 housekeeping genes from the FFPE samples
of 60 primary testicular DLBCLs utilizing the Nanostring
PanCancer Immune Profiling Panel. Unsupervised hierar-
chical clustering revealed three gene signatures differen-
tially expressed between the patients (Figure 1). We iden-
tified a large cluster of genes, which clearly separated the
patients. The core signature contained 121 genes (Online
Supplementary Table S1), which were enriched for T-cell
and NK-cell markers and signaling (e.g. CD3D/E/G, CD4,
CD8A/B, ITGB2, PRF1, GZMA/B/H/M/K, KLRB1/G1/K1)
(Online Supplementary Tables S1 and S2). This signature
was named  “T-lymphocyte signature”. In addition, two
minor cytokine signatures were recognized. “Cytokine
signature I” included 44 genes, enriched for cytokines (e.g.
CSF3, CSF2, IL3, IFNA1, IL5, IL11, IL2) (Online
Supplementary Table S2), whereas “Cytokine signature II”
included 25 genes, enriched for both cytokines and
cytokine receptors (e.g. IL4, IL17A, TNFRSF11A, IL17B,
TNFSF11, PPBP, IL9, CXCR1, TNFSF18, CCL28) (Online
Supplementary Table S3). 
T-lymphocyte signature is associated with survival in
patients with PTL
To study the association of the gene signatures with sur-
vival, we re-clustered samples according to the expression
Immunoprofiling and survival in PTL
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Figure 2. T-lymphocyte signature is associated with survival. (A) The gene expression data from 60 primary testicular lymphoma (PTL) patients were re-clustered
according to the expression of the T-lymphocyte signature genes. The data clustered into three groups: Group 1: low expression; Group 2: intermediate expression;
Group 3: high expression. (B) Kaplan-Meier (log-rank test) survival plots depict progression-free survival (PFS) and overall survival (OS) in the three patient groups.
(C and D) Kaplan-Meier plots show the PFS and OS of PTL patients stratified for the treatment with rituximab-containing regimen (C) versus no rituximab (D). (E and
F) RNA-seq data from the CGCI cohort with 96 de novo DLBCL cases was clustered based on the T-lymphocyte signature gene expression. This divided the patients
into two groups with higher (Group 2) and lower (Group 1) expression (E). Kaplan-Meier plots depict survival differences between the two groups (F).
A
C
B
D
FE
of the signature genes. Re-clustering the data based on the
expression of the 121 genes of the T-lymphocyte signature
separated the patients into three distinct groups with high,
intermediate and low expression (Figure 2A and Online
Supplementary Figure S1A). Interestingly, patients with low
expression of the T-lymphocyte signature genes (n=12)
had a significantly worse PFS, OS, and DSS in comparison
to patients with intermediate (n=32) and high (n=16) gene
expression (log-rank P=0.041, P=0.009, and P=0.033,
respectively) (Figure 2B and Online Supplementary Figure
S2A). In Cox multivariate analysis, low expression of T-
lymphocyte signature had prognostic impact on survival
independently of the International Prognostic Index  (IPI)
(PFS: HR=2.810, 95%CI: 0.228-6.431, P=0.014; OS:
HR=3.267, 95%CI: 1.406-7.590, P=0.006; and DSS:
HR=2.910, 95%CI: 1.004-8.436, P=0.049). This was evi-
dent for PFS and OS also with the individual IPI factors
(Online Supplementary Table S4). Baseline characteristics,
including age, molecular subgroup, stage, and IPI were
equally distributed in the subgroups with higher and
lower T-lymphocyte signature expression (Online
Supplementary Table S5). When the survival analyses were
adjusted according to treatment, adverse prognostic
impact of the low expression of T-lymphocyte signature
on outcome was particularly evident in the patients treat-
ed with the rituximab-containing regimen (Figure 2C and
D and Online Supplementary Figure S2B).
At the individual gene level, 72 genes from the T-lym-
phocyte signature were significantly (P<0.05) associated
with survival in Cox univariate analysis with continuous
variables and had lower expression in the poor prognosis
patient group (Online Supplementary Table S6). These
included, for example, T-cell surface markers (CD3D/E/G,
CD4, CD8A/B), cytolytic factors (PRF1, GZMA/K/M),
chemokines (CCL2/3/4/5), and killer-cell lectin-like recep-
tors (KLRB1, KLRG1, KLRK1). 
For the Cytokine I signature, no association with sur-
vival was found (data not shown). However, when patients
were re-clustered according to the expression of the 25
genes of the Cytokine II signature, they could be separat-
ed into two groups with higher and lower expression. The
group with higher expression of the Cytokine II signature
had a shorter 5-year PFS as compared to those with low or
no expression of the signature (36% vs. 66%; P=0.005)
(Online Supplementary Figure S3). In Cox multivariate
analysis with IPI, the Cytokine II signature was also found
to be an independent predictor of PFS (HR=3.393, 95%CI:
1.531-7.521; P=0.003). Baseline characteristics, including
age, molecular subgroup, stage and IPI were equally dis-
tributed in the subgroups with higher and lower expres-
sion of the Cytokine II signature (data not shown). In gener-
al, the absolute expression levels of the Cytokine II signa-
ture genes were low (Online Supplementary Figure S1B).
Low expression of the T-lymphocyte signature is 
associated with poor outcome in patients with 
de novo diffuse large B-cell lymphomas
Next, we tested whether the signatures could be identi-
fied also from other B-cell lymphomas. To this end, we
used RNA-sequencing data from 96 primary DLBCL
patients from the Cancer Genome Characterization
Initiative (CGCI) cohort (Table 1). Following hierarchical
clustering of the gene expression of the T-lymphocyte sig-
nature, a subgroup of patients with low expression of the
signature was identified (Figure 2E and Online
Supplementary Figure S1C). This group of patients had
shorter survival as compared to patients with higher
expression of the signature genes (PFS: P=0.007, OS:
P=0.034) (Figure 2F). In a multivariate analysis with IPI,
low T-lymphocyte signature remained  an independent
prognostic factor for PFS (HR=2.560, 95%CI: 1.151-5.695;
P=0.021). The baseline characteristics were equally dis-
tributed between the patient groups (Online Supplementary
Table S5). The results indicate that the T-lymphocyte sig-
nature identified from the PTL cohort has prognostic
impact on survival also in patients with de novo DLBCL.
On the contrary, genes from the cytokine signatures were
neither differentially expressed between the patients or
associated with survival in DLBCL (data not shown). As in
PTL, the absolute expression levels of the cytokine signa-
S-K. Leivonen et al.
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Table 3. Univariate and multivariate Cox regression survival analysis of
multiplex immunohistochemistry data.
HRa 95% CI P
Univariate
PFS
CD3+ 3.675 1.195-11.299 0.023
CD3+CD4+ 3.766 1.225-11.573 0.021
CD3+CD8+ 2.738 0.870-8.614 0.085
OS
CD3+ 5.461 1.552-19.214 0.008
CD3+CD4+ 4.813 1.355-17.100 0.015
CD3+CD8+ 3.957 1.102-14.212 0.035
DSS
CD3+ 9.889 1.235-79.200 0.031
CD3+CD4+ 9.495 1.186-76.004 0.034
CD3+CD8+ 6.512 0.783-54.148 0.083
Multivariate
PFS
CD3+ 4.706 1.494-14.829 0.008
IPI 4.476 1.969-10.174 <0.001
CD3+CD4+ 4.114 1.327-12.755 0.014
IPI 4.107 1.797-9.387 0.001
CD3+CD8+ 2.861 0.906-9.041 0.073
IPI 3.620 1.653-7.928 0.001  
OS
CD3+ 7.265 2.007-26.302 0.003
IPI 5.639 2.382-13.348 <0.001
CD3+CD4+ 5.244 1.463-18.801 0.011
IPI 4.747 2.003-11.250 <0.001
CD3+CD8+ 4.024 1.116-14.512 0.033
IPI 4.125 1.816-9.369 0.001
DSS
CD3+ 15.219 1.804-128.374 0.012
IPI 16.477 4.782-56.777 <0.001
CD3+CD4+ 10.150 1.243-82.889 0.031
IPI 13.623 3.987-46.546 <0.001
CD3+CD8+ 6.744 0.799-56.923 0.079
IPI 11.576 3.562-37.616 <0.001
IPI: International Prognostic Index. aHR: hazard Ratio; IPI: International Prognostic
Index. CI: Confidence Interval.  PFS: progression-free survival; OS: overall survival; DSS:
disease-specific survival;
ture genes were low (data not shown), suggesting that they
are not clinically relevant.  
Low amount of tumor-infiltrating T cells is associated
with poor outcome in patients with PTL
To study the presence of different T-cell and NK-cell
subtypes in the tumor milieu, we performed mIHC with
CD3, CD4, CD8, and CD56 cell surface markers on a
TMA of 60 PTL patients (Figure 3A and Online
Supplementary Figure S4). The relative levels of tumor-infil-
trating CD3−CD56+ cells were very low (median 0.3%,
range 0.0-52.7%), and there were no significant differ-
ences in the amount of CD56+ cells between the good and
poor prognosis groups (data not shown). However, mIHC
analysis confirmed significantly (P<0.001) lower propor-
tions of CD3+, CD3+CD4+, and CD3+CD8+ lymphocytes in
patients with a poor prognosis in comparison to patients
with a favorable outcome (Figure 3B). Expression of CD3,
CD4, and CD8 at the protein level correlated with the cor-
responding gene expressions (Spearman P=0.779,
P<0.001; P=0.645, P<0.001; and P=0.768, P<0.001, respec-
tively). Furthermore, low amounts of tumor-infiltrating
CD3+, CD3+CD4+, and CD3+CD8+ lymphocytes were
associated with a poor outcome (Online Supplementary
Figure S5), which was independent of IPI (Table 3).
Consistent with the findings on the gene expression level,
an adverse prognostic impact of the low tumor-infiltrating
CD4+ and CD8+ T-cell counts was particularly evident in
patients treated with the rituximab-containing regimen
(Online Supplementary Figure S6).
Loss of membrane-associated HLA class I and II
expression is frequent in PTL
Loss or aberrant expression of HLA molecules may
cause tumor cells to escape from immunosurveillance.
Here, the expression of HLA I and HLA II genes was
lower in the poor prognosis group of PTL patients
(P<0.05) (Online Supplementary Figure S7A). This was evi-
dent also in the de novo DLBCL cohort (Online
Supplementary Figure S7B). 
To study the subcellular localization of HLA class I and
II, we analyzed HLA-DR, HLA-ABC and β2M, a compo-
nent of HLA I, immunohistochemically (Figure 4A). A
minority of the PTL cases showed highly positive mem-
brane staining for HLA-DR, HLA-ABC, and β2M (17%,
28%, and 13%, respectively) (Table 4). Interestingly,
triple-positive membrane staining of HLA I, HLA II and
β2M was associated with a higher number of tumor-infil-
trating CD3+, CD3+CD4+, and CD3+CD8+ lymphocytes
(Figure 4B).
Discussion
The TME plays an important role in lymphoma patho-
genesis and patient prognosis.3 In this study, we aimed to
characterize the immunological profiles and their associa-
tion with outcome in patients with PTL. We found that a
gene signature enriched for T-cell genes was associated
with outcome in patients treated with chemotherapy and
immunochemotherapy. We could further demonstrate
that lower amounts of tumor-infiltrating CD4+ and CD8+
T cells was associated with a poor prognosis in patients
with PTL. The impact was particularly evident among
patients treated with rituximab-containing
immunochemotherapy. The limitation of our study is the
lack of a proper validation cohort due to the rare nature of
Immunoprofiling and survival in PTL
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Figure 3. Lower number of tumor-infiltrating T cells is associated with poor survival in primary testicular lymphoma (PTL). (A) Representative images (high, inter-
mediate, low) from mIHC analysis of PTL tumor-associate macrophages probed with a 4-plex panel of T-cell markers. Blue: CD3; red: CD8; white: CD4; green: CD56;
gray: DAPI. Scale bars 50 µm (upper panel) and 20 mm (lower panel). Images from individual channels are presented in Online Supplementary Figure S4. (B) Boxplots
visualizing the expression of CD3+, CD3+CD4+, and CD3+CD8+ lymphocytes in the three groups based on the T-lymphocyte signature (1: poor prognosis, 2: intermedi-
ate, and 3: better prognosis). Statistical significance was determined by Kruskall-Wallis test.   
Table 4. HLA and β2M immunohistochemical staining results.
β2M HLA-ABC HLA-DR
% % %
Negative 31.7 18.3 53.3
Moderately positive 55.0 53.3 30.0
Highly positive 13.3 28.3 16.7
A B
PTL. However, the T-lymphocyte signature had a prog-
nostic impact in an independent cohort of de novo DLBCL
patients treated with immunochemotherapy, demonstrat-
ing the importance of the signature genes also in other
aggressive B-cell lymphomas. Our data extend previous
findings on DLBCL patients treated with CHOP and R-
CHOP-like regimens.16-18 Together, the results emphasize
the important role of the T-cell inflamed TME in regulat-
ing therapy resistance in PTL.
T lymphocytes, mostly comprising CD4+ and CD8+ T
cells, play a major role in cell-mediated immunity.
Lymphoma cells have been shown to escape immunosur-
veillance due to loss of expression or mislocalization of
HLA I and II molecules.7-11,19 We found that reduced mem-
branous staining of HLA I and II molecules and β2M cor-
related with lower T-cell infiltration, implying that defects
in HLA complexes may impair the recruitment of the
tumor-infiltrating T-cell subsets. 
Indeed, our data suggest that immune escape does not
only provide a mechanism for lymphoma pathogenesis,
but also plays a role in promoting resistance to
immunochemotherapy. We propose that lymphomas
with inflammatory profile characterized by high content
of tumor-infiltrating CD4+ and CD8+ T cells, “the hot
tumors”, display pre-existing antitumor immune response.
In response to therapy, and particularly rituximab-contain-
ing regimen, tumor-infiltrating T cells are stimulated fur-
ther to participate in immune response against lymphoma
cells. In contrast, lymphomas that lack T-cell infiltration,
“the cold tumors”, reflect the absence of pre-existing anti-
tumor immunity and have a lower likelihood of having an
optimal response  to therapy. Consistent with our hypoth-
esis, it has been shown that many chemotherapeutic
drugs, including cyclophosphamide and doxorubicin,
which are the main components in the CHOP regimen,
can activate anti-tumor immune response by increasing
immunogenicity of malignant cells as well as by directly
relieving immunosuppressive networks.20 Rituximab and
other therapeutic CD20 antibodies can, in turn, further
promote a long-term anti-tumor immune response, called
the “vaccinal” effect, which is dependent on the presence
of both CD4+ and CD8+ lymphocytes.21-23 Further studies
should aim to characterize in more detail the underlying
mechanisms for the loss of T-cell trafficking and infiltra-
tion. For example, differences in the mutational density
between the T-cell inflamed “hot” and non-inflamed
“cold” tumors might explain the loss of T cells in a subset
of tumors. Additional gene expression profiling studies
could provide information as to which genes and molecu-
lar pathways are differentially expressed or activated in
the T-cell inflamed and non-inflamed tumors, and thus
might mediate T-cell exclusion from the TME. For exam-
ple, in melanoma and bladder cancer, the Wnt/β-catenin
pathway has been shown to be causal in preventing T-cell
activation and trafficking into the tumor microenviron-
ment.24,25 In addition, it would be interesting to examine
the distribution of other cell lineages and their pheno-
types, and determine whether PTLs express other
immunoregulatory molecules, including PD-L1, LAG-3 or
IDO-1 and IDO-2, which can be targeted by novel thera-
pies.
Recently, we showed that tumor-associated
macrophages (TAMs) play a major role in PTL.26 High infil-
tration of PD-L1+CD68+ TAMs was associated with favor-
able survival and correlated with CD4+ and CD8+ T cells
positive for PD1. In addition, both PD-L1+ TAMs and 
PD-1+ T cells emerged as independent indicators of sur-
vival for the patients with PTL. The interaction of PD-L1+
TAMs and PD-1+ T cells may modify the TME in PTL, or
otherwise promote an anti-tumor immune response fol-
lowing immunochemotherapy.
The poor outcome associated with a low tumor-infil-
trating T-cell content might provide the objective for  ther-
apeutic interventions. Cancer immunotherapy, especially
protocols aiming to activate T-cell-mediated anti-tumor
responses, and T-cell trafficking into the non-inflamed
S-K. Leivonen et al.
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Figure 4. Loss of membrane-associated HLA class I and II expression is frequent in primary testicular lymphoma (PTL) and correlates with low T-cell infiltration.
(A) Representative images of HLA-ABC, HLA-DR, and β2 microglobulin antibody of PTL tissue sections. The samples were scored as negative (neg), moderately pos-
itive (pos), and highly positive according to the membrane staining. Scale bar 50 mm. (B) Boxplots visualizing the correlation of HLA-ABC, HLA-DR and β2M triple-
positive membrane staining (either moderate or high membrane staining) with T-cell numbers in PTL (n=14 and n=46 in positive and negative groups, respectively).
P-values were determined by Mann-Whitney test.
A B
tumors has indeed gained a lot of attention recently.
Antibodies targeting inhibitory molecules, such as PD-1,
PD-L1, and CTLA-4 that regulate T-cell cytotoxicity have
achieved impressive clinical responses.27-29 However,
despite clear clinical responses, only a fraction of patients
respond to treatment. Based on the findings from solid
tumors, it has been suggested that the status of the HLA
machinery affects the success of immunotherapy. For
example, inactivating mutations in the β2M and HLA I
complex in lung cancer caused a lack of response to
immunotherapy because the cytotoxic cells were unable
to find and attack the tumor cells.30 It was suggested that
the recurrent inactivation of HLA I is an acquired mecha-
nism for avoiding tumor immune recognition. In lym-
phomas, novel immunotherapies, including bispecific
antibodies, cancer vaccines, and chimeric antigen receptor
(CAR)-T cells may help T cells to identify and attack can-
cer cells.31-36 Another therapeutic implication that could be
tested is to recuperate the loss of HLA II expression and
the subsequent inability of T cells to recognize lymphoma
cells by using histone deacetylase inhibitors.37,38
In conclusion, we have combined immune gene signa-
tures and mIHC data with clinical information in a cohort
of patients with PTL. We found three immune signatures,
of which the T-lymphocyte signature was associated with
survival both in PTL and DLBCL. The patients with T-cell-
inflamed TME had a significantly increased risk of pro-
gression and death independently of IPI. Furthermore,
reduced membranous staining of HLA I and II correlated
with low T-cell infiltration. Taken together, the results
presented herein are novel and emphasize the importance
of immune escape as a mechanism regulating therapy
resistance in patients with PTL.
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